<DOC>
	<DOC>NCT01002274</DOC>
	<brief_summary>This is an open-label extension study of another study protocol, MCS-2-TWN-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for this study.</brief_summary>
	<brief_title>Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms</brief_title>
	<detailed_description>This open-label extension study is designed to further assess the long-term safety and efficacy of MCS-2. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for another 40 weeks of MCS-2 treatment at the same daily dosage as the active treatment given under the protocol MCS-2-TWN-a. Subjects are limited to those who are currently not being treated medically for BPH or LUTS.</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Subject has completed 12 weeks of treatment under the protocol MCS2TWNa. Subject is able to understand and willing to conform to the study procedures and has signed the informed consent form for participation in this extension study. Subject has severe LUTS at the last visit under the protocol MCS2TWNa. Subject is considered ineligible for the study by the investigator(s).</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>MCS-2</keyword>
	<keyword>Multi-Carotenoids</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
	<keyword>International prostate symptom score</keyword>
</DOC>